Carcinoma of Unknown Primary Clinical Trial
Official title:
A Phase II Study Of Gemcitabine (GEMZAR) And Irinotecan (CPT-11) In Previously Untreated Patients With Measurable Disease With Unknown Primary Carcinoma
RATIONALE: Drugs used in chemotherapy such as gemcitabine and irinotecan use different ways
to stop tumor cells from dividing so they stop growing or die. Combining more than one drug
may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving gemcitabine together with
irinotecan works in treating patients with cancer of unknown primary origin.
OBJECTIVES:
Primary
- Determine the response rate in patients with carcinoma of unknown primary when treated
with gemcitabine and irinotecan.
- Determine the adverse event profile and tolerability of this regimen, based on the
presence or absence of the UGT1A1*28 polymorphism, in these patients. (Cohort I closed
to accrual 11/17/05)
- Determine the adverse event profile and tolerability of this regimen. (Cohort II)
Secondary
- Determine the time to progression and overall survival of patients treated with this
regimen.
- Correlate patterns of immunohistochemical staining with response in patients treated
with this regimen.
- Correlate variation in multiple different genes, whose protein products are involved in
the uptake, metabolism, and distribution of these drugs, with clinical outcomes, in
terms of response and toxicity, in these patients.
- Determine primary origin of cancer of unknown primary samples by completing a 92-gene
RT-PCR cancer classification assay.
- Determine whether the 92-gene assay results are correlated with clinical response to
gemcitabine and irinotecan.
OUTLINE:
- Cohort I (closed to accrual 11/17/05): Patients receive gemcitabine IV over 30 minutes
and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be
escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6
weeks in the absence of disease progression or unacceptable toxicity.
- Cohort II: Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90
minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease
progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00003943 -
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
|
Phase 2 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Recruiting |
NCT02590055 -
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
|
Phase 2 | |
Completed |
NCT00002507 -
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Recruiting |
NCT03740503 -
Genomic Investigation of Unusual Responders
|
||
Terminated |
NCT00148135 -
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
|
Phase 2 | |
Completed |
NCT00003582 -
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00014456 -
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
Completed |
NCT00357630 -
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
|
Phase 2 | |
Active, not recruiting |
NCT01366144 -
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Completed |
NCT00004922 -
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00119314 -
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00047125 -
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
|
Phase 3 | |
Completed |
NCT00003657 -
High-dose ICE With Amifostine
|
Phase 2 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Recruiting |
NCT02764216 -
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
|
Phase 2 | |
Completed |
NCT00873119 -
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
|
Phase 2 | |
Completed |
NCT00388024 -
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
|
N/A |